KMAK Capital Announces Strategic Investment in Avvio Medical to Advance Kidney Stone Treatment Innovation

Scottsdale, AZ – November 11, 2024 – KMAK Capital, a family office rooted in values-based strategic investments, is excited to announce its recent investment in Avvio Medical, an innovator in non-invasive kidney stone treatment technology. Avvio Medical's ultrasound-based solutions provide a safer, patient-focused alternative to traditional procedures, aiming to improve care and accessibility.

"Avvio Medical aims to change the standard of care for the treatment of patients with urinary stone disease. Our novel office-based procedure enables shorter wait times without requiring fluoroscopy or general anesthesia, thereby reducing overall medical costs.

Our innovative technology employs low-pressure ultrasound to actuate calcium-seeking microbubbles, creating millions of micro-jets eroding the stone.*" Source: Avvio Medical, Avvio Medical Website

Image courtesy of Avvio Medical

Avvio Medical Website

This partnership reflects KMAK Capital’s commitment to staying close to patients, creating value that prioritizes patient outcomes. KMAK believes in the power of values-driven investments to benefit patients, providers, and communities alike through healthcare innovations that align with sustainable, patient-first practices.

Contact:

Avvio Medical

info@avviomed.com

Website: https://avviomedical.com/

KMAK Capital

Info@KMAKCapital.com

Website: www.kmakcapital.com

CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

Disclaimer: Avvio Medical, Inc. does not currently offer medical devices for sale or distribution and the company’s technology has not received market clearance status by the U.S. FDA or any other country’s regulatory authority.